Alembic Pharma gets EIR from USFDA for Karakhadi facility

Aleor Dermaceuticals Ltd, the 60:40 joint venture between Alembic Pharmaceuticals Ltd and Orbicular Pharmaceutical Technologies Pvt Ltd, has received an establishment inspection report (EIR) from United States Food & Drug Administration (USFDA).

The EIR is for the inspection carried out by USFDA at Aleor's formulation facility in Karakhadi (Gujarat) during the period from January 6 to 8, 2020.

This week, Alembic’s general oral solid formulation facility located at Panelav (Gujarat) was classified as voluntary action indicated (VAI) by USFDA. VAI means USFDA accepted the company’s response to its observations.

Alembic Pharma is engaged in developing formulations and active pharmaceutical ingredients (API). The company focusses on anti-infective, analgesic and cough & cold therapies. It also focusses on therapies, such as cardiology, diabetes, gynecology, gastrointestinal, orthopedic, dermatology and ophthalmology.

On Wednesday, the stock of Alembic Pharma surged 4.4 per cent to Rs 785 in the morning trading session from its previous close of Rs 751.75 on BSE.